

OncoPortal™ Plus

APP NOTE



Streamline clinical interpretation of comprehensive genomic profiling with OncoPortal™ Plus

Comprehensive genomic profiling (CGP) of tumors using next-generation sequencing (NGS) is increasingly being used to aid decision making. These broad sequencing panels have the potential to identify more possible treatment targets than smaller panels, but generate hundreds of variants so that pinpointing actionable information is challenging. Complex molecular profiles of SNVs/Indels, copy number variations (CNVs), fusions, microsatellite instability (MSI) status and tumor mutational burden (TMB) need to be consistently, accurately, and efficiently interpreted without missing key actionable insights. The key findings then need to be summarized in a comprehensive genomic report that can be customized to individual preferences and standards.

OncoPortal™ Plus is an evidence-based decision support software fully integrated into the SOPHiA DDM™ workflow to aid the interpretation of genomic variants identified through NGS assays (Figure 1). SOPHiA DDM™ automatically detects, annotates, and pre-classifies genomic variants from raw sequencing data. Subsequently, the user-friendly OncoPortal™ Plus web application, exclusively accessible through SOPHiA DDM™, characterizes biomarkers associated with specific solid and hematological malignancies and their Clinical Associations (including available therapies, clinical trials, diagnosis, and prognosis) using published literature and guidelines. Finally, laboratories can customize state-of-the-art comprehensive genomic and genetic reports using an unlimited number of customizable templates to address their unique needs.




Figure 1. SOPHiA DDM™ workflow with integrated OncoPortal™ Plus and reporting.

Here, we will demonstrate the power of OncoPortal™ Plus for the interpretation of genomic data obtained with SOPHiA DDM™ for TruSight® Oncology 500 (TSO500). TSO500 is a CGP assay that profiles >500 genes to detect multiple variant types and complex biomarkers such as MSI and TMB.

OncoPortal™ Plus is able to identify variants (biomarkers) and their Clinical Associations from SOPHiA DDM™ for TSO500, facilitating the generation of detailed and intuitive reports to support decision making.

1. Starting variant interpretation in the SOPHiA DDM™ Platform

When accessing SOPHiA DDM™, all available applications (bioinformatic workflows) are displayed on the Dashboard (Figure 2). When SOPHiA DDM™ has completed the TSO500 sequencing analysis, users receive an email notification to securely log in and begin the interpretation. Clicking on “TruSight Oncology500” provides access to the TSO500 workspace.




Figure 2. SOPHiA DDM™ home screen displaying all available applications.

2. Initiating a new interpretation project

The TSO500 workspace automatically displays all available runs and samples, ready for interpretation. To start the assessment of Sample 01-153-19, we create a “New Interpretation Project”. First, click “add interpretation”, select the disease from a drop-down menu (in this case “Colorectal cancer”), give the interpretation a name, and click “Finish” (Figure 3).




Figure 3. SOPHiA DDM™ TSO500 workspace, and initiation of a new interpretation project for the selected sample.

3. Viewing an overview of a sample’s genomic variants

After creating a new interpretation project, the platform offers a glimpse of the detected variants in the “Overview” tab (Figure 4). This tab provides a high-level summary of the findings, including the number of variants, retained variants, MSI status, and TMB.




Figure 4. SOPHiA DDM™ Overview tab for the selected sample.

4. Accessing OncoPortal™ Plus through SOPHiA DDM™

There are two ways to review SNVs/Indels, fusions, and CNVs. The variants can be reviewed individually in the “Variants” tab in SOPHiA DDM™, or the results can be interpreted using OncoPortal™ Plus by clicking on the “OncoPortal” tab. Clicking on “OncoPortal” will display a pop-up that gives the option to access the “NEW OncoPortal web app!” or “Legacy OncoPortal” (Figure 5). We will explore OncoPortal™ Plus through the new OncoPortal web app.




Figure 5. Access to OncoPortal™ Plus via SOPHiA DDM™.

5. Viewing Molecular Profiles in the OncoPortal™ Plus web application

OncoPortal™ Plus opens as a new web browser window. Information flows securely between the SOPHiA DDM™ Platform and the web application, so that the top panel of OncoPortal™ Plus is automatically populated with the same case details as in SOPHiA DDM™ (Figure 6). Viewing OncoPortal™ Plus in a web browser allows multiple projects to be opened at the same time, in different tabs.

The web application has a range of intuitive features. On the left-hand side, it is possible to switch between “Molecular Profiles” and “Clinical Trials” views. The “Molecular Profiles” view is a key feature of OncoPortal™ Plus. Molecular Profiles detail interactions between co-occurring biomarkers, which are listed in the main table. This display captures the potential biological interaction of different biomarkers present in the same sample. For example, one biomarker might indicate sensitivity to a targeted agent, whereas another co-occurring biomarker might indicate resistance to the same agent. Rather than considering each variant individually, this feature supports the assessment of the relationship between multiple tumor alterations and their compound impact on therapeutic efficacy, diagnosis, prognosis, or access to clinical trials.




Figure 6. OncoPortal™ Plus web application Molecular Profiles display for a selected sample.

6. Filtering Molecular Profiles

A useful feature in OncoPortal™ Plus is the ability to filter the results and focus on the most actionable information first. Filters include cancer type (disease), AMP/ASCO/CAP tier, association type, approval authority (FDA, EMA, TGA), and response type (therapy, diagnosis, prognosis) (Figure 7). After filtering, it is possible to rank the results in different orders, according to preference.




Figure 7. Filtering feature in OncoPortal™ Plus.

7. Exploring Molecular Profiles

After filtering and ranking, in this example, the number of Molecular Profiles was narrowed down from 256 to 5. *BRF V600E* was identified as the most relevant variant (Figure 8). To explore this biomarker in more detail, click on the associated Molecular Profile and then click “i” next to the variant name. This displays rich interpretive information related to both normal gene function and biomarker function, supported by up-to-date scientific sources.

We also see a list of Clinical Associations related to the *BRF V600E* Molecular Profile in the main table. The labels on the right enable a quick review of the key details, such as whether the biomarker is sensitive or resistant to the targeted agent, therapy approval status, clinical trial phase, and AMP/ASCO/CAP tier/evidence level.




Figure 8. Further exploration of the *BRF V600E* Molecular Profile in OncoPortal™ Plus.

8. Gaining additional insights into Clinical Associations for a given biomarker

Clicking on a Clinical Association reveals additional details, such as the mechanism of action of a given drug (Figure 9). Molecular Profiles can be added to the report by selecting the Clinical Association of interest and checking the “Add selection to report” box, or by clicking the “Add to report” button when viewing the Clinical Association. The entry can be customized with a user-entered note, e.g., to explain why a specific Molecular Profile and Clinical Association have been selected.




Figure 9. Further details about Clinical Associations and adding items to the OncoPortal™ Plus report.

9. Customizing templates for comprehensive reports




Figure 10. The SOPHiA DDM™ Template Manager Editor for configuring custom reporting templates.

In SOPHiA DDM™, the Template Manager provides a user-friendly interface for the preparation of custom reporting templates (Figure 10). First, we select one of the provided templates. Then, the Editor can be used to activate/deactivate, rename, and configure individual report sections (stencils) with granular information fields. The final customized template can be previewed and saved, and then used for subsequent reports.

10. Completing a comprehensive genomic report

During the clinical interpretation, information flows securely between OncoPortal™ Plus and SOPHiA DDM™, so that after selecting Molecular Profiles and Clinical Associations in OncoPortal™ Plus, the report can be completed in the SOPHiA DDM™ Overview tab (Figure 11), where the case information can be edited, and the Conclusion written. The 'Complete' button launches the web-based Reporting app (Figure 12), where a previously configured template can be selected. The reporting app populates the template with the case, biomarker, and interpretive information from OncoPortal™ Plus and SOPHiA DDM™. Approval of the final report can then be initiated from the reporting app, so that the approver is notified that the report is ready for review and approval.

The screenshot shows the 'Overview' tab in the SOPHiA DDM™ interface. The top navigation bar includes 'WORKSPACE Requests', 'VDB Variant Database Browser', 'SIS Integrated Solutions', and 'ANALYSIS 01-153-19 #3-0456'. Below this, there are tabs for 'Overview', 'OncoPortal', and 'Variants'. The 'Overview' tab is active and contains a 'TEST' summary with the following data:

- GENES: 7606
- VARIANTS: 1322
- RETAINED: 6284
- LOW CONFIDENCE: 6284
- High MSI Status
- 46.2 mut/Mb TMB aLI
- 36.2 mut/Mb TMB non-syn
- VARIANT DEPTHS: 4
- DEPTH MIN

On the right side, there is a 'Patient' section with 'Interpretation 1' and 'Draft' status. Below this, there are fields for 'Virtual Panel' (TruSight_Oncology500 (688 genes)), 'Date created' (02/12/2021), and 'Owner' (Marian Novak). A 'Project Settings' section includes 'Delete' and 'Complete' buttons. A large 'Conclusion' text area is highlighted with a red box, indicating where the user would enter their final interpretation.

Figure 11. The SOPHiA DDM™ Overview tab for completion of the report.

The screenshot shows the 'Reporting' app interface in a web browser. The URL is 'pre-prod.sophigenetics.com/app/reporting/report/generator/'. The main content area is titled 'Variant Report' and contains the following information:

- Patient Information:** First name: Nathan, Last name: Taylor Davies, Date of Birth: 4 NOV 1965, Gender: Male, Patient ID: 01-153-19, Pathology: Colorectal cancer.
- Ordering Physician:** Dr. Evans
- Specimen Information:** Specimen ID: 01-153-19, Specimen Type: Excisional Biopsy, Preservation method: FFPE, Specimen Collected: -, Specimen Received: -
- Specimen selected by:** Laboratory Clinic Rochester, 123 Main Street Springfield XY123456, USA
- Conclusion:** Given the actionable biomarkers identified in the patient, a suggested therapy can be combination of Cetuximab and Encorafenib, Ipilimumab and Nivolumab, and Pembrolizumab. Additional systemic therapy to be considered. Patient needs to be re-assessed for clinical progression.
- Overview:**
 - Result: Actionability identified
 - Tumor cell %: 40%
 - MSI status: High
 - TMB (aLI): 46.2 mut/Mb
 - TMB (non-synonymous): 36.2 mut/Mb
 - 3 Actionable biomarkers
 - 4 Therapies with potential benefit in tumor
 - 0 Therapies with potential benefit in different tumor
 - 0 Therapies with lack of potential benefit
- Summary:**
 - Application: TruSight Oncology 500
 - About the test: -
 - Referral reason: Colorectal cancer
- Actionable biomarkers:** BRAF V600E, MSI high, TMB high
- Therapies with potential benefit in tumor:** Cetuximab + Encorafenib, Ipilimumab + Nivolumab, Pembrolizumab, Pembrolizumab
- Therapies with potential benefit in different tumor:** -
- Therapies with lack of potential benefit:** -
- Prognostic biomarkers:** 0
- Diagnostic biomarkers:** 0
- Biomarkers with potential clinical significance:** 0
- Patient clinical history:** Nathan is a 56 years old male with metastatic colorectal cancer. This patient presented with a 2-month history of bloating and abdominal discomfort. His last colonoscopy was about 2 years ago and was negative, and he also had some unintentional weight loss. With regard to his past medical history, it's significant only because of high blood pressure, which is controlled with lisinopril.

On the right side, there is a 'MY REPORT' section with a 'Template' dropdown menu set to 'Default Somatic Oncoportal Repor'. Below this, there are fields for 'Sample' (01-153-19), 'Test' (TruSight Oncology 500 (somatic)), 'Type' (somatic), and 'Report status' (Draft). There are 'Complete' and 'Request approval' buttons.

Figure 12. Automatic population of information from OncoPortal™ Plus and SOPHiA DDM™ into a previously configured template in the Reporting app.

Conclusion

OncoPortal™ Plus is a user-friendly module of SOPHiA DDM™, integrated into the platform's streamlined sample-to-report workflow. The OncoPortal™ Plus web application intuitively displays and reviews co-occurring biomarkers as Molecular Profiles, to reduce the chance of missing interfering variants and speed up interpretation. Molecular Profiles can be filtered to display the most actionable biomarker first, further streamlining assessment. OncoPortal™ Plus provides detailed descriptions of gene and biomarker functions, and rich information to support the Clinical Associations between Molecular Profiles and therapeutic options, clinical trials, diagnosis, and prognosis of specific cancer types, using up-to-date published scientific sources.

OncoPortal™ Plus gives users the confidence to make fast decisions with consistent and accurate interpretation of clinically significant biomarkers. Users are able to save time and reduce errors from manual interpretation of comprehensive data sets like the TSO500 CGP, and can efficiently communicate results via customizable, comprehensive, state-of-the-art reports generated in SOPHiA DDM™.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

Want to know more?

Contact us at:

info@sophiagenetics.com



OncoPortal™ Plus is for Clinical Decision Support Use Only - Not intended as a primary diagnostic tool.

SOPHiA DDM™ for TSO500 is for Research Use Only and is not intended for purposes other than research. SOPHiA DDM™ for TSO500 is not for diagnostic, therapeutic, or treatment purposes.

© 2022 SOPHiA GENETICS. All rights reserved. All trademarks are the property of SOPHiA GENETICS and/or its affiliate(s) in the U.S. and/or other countries. All other names, logos, and other trademarks are the property of their respective owners.